Dalian - The Business Case for Tackling AIDS

The Business Case for Tackling AIDS In 2006, the world spent US$ 9 billion on AIDS. Nonetheless, experts anticipate that AIDS will lead to reduced workforce productivity and increased medical costs for businesses. The private sector has the potential to significantly reduce the impact of AIDS through specific expertise and innovation. 1) What are the key challenges and opportunities in tackling AIDS? 2) What role can the new business champions play? 3) What innovations are possible in service delivery, diagnosis and treatment technologies and sustainable financing? Discussion Leader Bo Shao, Chairman, Novamed Pharmaceuticals, People's Republic of China; Young Global Leader Rajat K. Gupta, Senior Partner, McKinsey & Co., USA, and Chairman of the Board, The Global Fund to Fight AIDS, Tuberculosis and Malaria; Member of the Foundation Board of the World Economic Forum Peter Piot, Executive Director, Joint United Nations Programme on HIV/AIDS (UNAIDS) and Undersecretary-General, United Nations, Geneva Wang Longde, Vice-Minister of Health of the People's Republic of China Facilitated by Christine Ockrent, Editor-in-Chief and Author, France 3, France